Takeda doubles down on F-star's dual-targeting antibody tech

22 March 2023
biotech_lab_research_2022_big

A British subsidiary of China’s Sino Biopharmaceutical (HKEX: 1177) has entered into a second licensing deal with Takeda Pharmaceutical (TYO: 4502).

Japan’s largest drugmaker is expanding a collaboration with F-star Therapeutics, a UK and USA-based biotech which was bought by Sino’s UK-based business invoX Pharma in June 2022.

The deal will give Takeda a global license for a novel next-generation antibody, directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab and mAb2 platforms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology